Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.77 |
| ▸ | GAA | P10253 | 5/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.77 |
| ▸ | RAB9A | P51151 | 2/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.77 |
| ▸ | NPC1 | O15118 | 1/20 | 0.77 |
| ▸ | THRB | P10828 | 1/20 | 0.77 |
| ▸ | RECQL | P46063 | 1/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.77 |
| ▸ | MAOA | P21397 | 2/20 | 0.63 |
| ▸ | MAOB | P27338 | 2/20 | 0.63 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.63 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19660767 | 0.94 | MAPT (0.68) | MAPTGAAKDM4ERAB9AMAPK1 | |
| SCHEMBL39057 | 0.88 | MAPT (1.00) | MAPTGAAKDM4ERAB9AMAPK1 | |
| SCHEMBL1459772 | 0.88 | MAPT (1.00) | MAPTGAAKDM4ERAB9AMAPK1 | |
| SCHEMBL7024215 | 0.85 | — | — | |
| SCHEMBL8298 | 0.85 | — | — | |
| SCHEMBL7844969 | 0.82 | MTNR1B (0.64) | MAPTGAAKDM4ERAB9AMAPK1 | |
| SCHEMBL1921511 | 0.81 | MAPT (0.85) | MAPTGAAKDM4ERAB9AMAPK1 | |
| SCHEMBL7758813 | 0.81 | RAB9A (0.85) | MAPTGAAKDM4ERAB9AMAPK1 | |
| SCHEMBL12648780 | 0.81 | MAPT (0.85) | MAPTGAAKDM4ERAB9AMAPK1 | |
| SCHEMBL8943931 | 0.81 | MAPT (0.85) | MAPTGAAKDM4ERAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410364-B2 | Electrochromic composition and electrochromic device | TAI YING OPTRONICS CO., LTD. (TW) | 2025-09-09 | — | — | US | disclosed |
| CN-117925215-A | Electrochromic composition and electrochromic device | 泰盈光电股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20240085753-A1 | ELECTROCHROMIC COMPOSITION AND ELECTROCHROMIC DEVICE | TAI YING OPTRONICS CO., LTD. (TW) | 2024-03-14 | — | — | US | disclosed |
| US-11572348-B2 | Syntheses of N-heterocyclic carbenes and intermediates therefor | UMICORE AG & CO. KG (DE) | 2023-02-07 | — | — | US | disclosed |
| US-20230009845-A1 | ORGANIC ELECTRIC ELEMENT COMPRISING A PLURALITY OF EMISSION-AUXILIARY LAYERS AND ELECTRONIC DEVICE COMPRISING IT | DUK SAN NEOLUX CO., LTD. (KR) | 2023-01-12 | — | — | US | disclosed |
| US-11205755-B2 | Compound for organic electronic element, organic electronic element using same, and electronic device thereof | DUK SAN NEOLUX CO., LTD. (KR) | 2021-12-21 | — | — | US | disclosed |
| US-20210317088-A9 | SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR | UMICORE AG & CO. KG (DE) | 2021-10-14 | — | — | US | disclosed |
| US-20200354323-A1 | SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR | UMICORE AG & CO. KG (DE) | 2020-11-12 | — | — | US | disclosed |
| US-10759763-B2 | Syntheses of N-heterocyclic carbenes and intermediates therefor | UMICORE AG & CO. KG (DE) | 2020-09-01 | — | — | US | disclosed |
| US-20190296248-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING SAME AND ELECTRONIC DEVICE THEREFOR | DUK SAN NEOLUX CO., LTD. (KR) | 2019-09-26 | — | — | US | disclosed |
| US-20090221820-A1 | Ligands for Transition-Metal-Catalyzed Cross-Couplings, and Methods of Use Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221820-A1 | Ligands for Transition-Metal-Catalyzed Cross-Couplings, and Methods of Use Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2009076622-A2 | LIGANDS FOR TRANSITION-METAL-CATALYZED CROSS-COUPLINGS, AND METHODS OF USE THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090062341-A1 | Nuclear receptor binding agents | GTX, INC | 2009-03-05 | — | — | US | disclosed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | disclosed |
| EP-0731091-B1 | 2-OXOINDOLINE DERIVATIVES AS CHOLECYSTOKININ RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-5807883-A | GASTROINTESTINAL DISORDERS; PANCREATITIS | TANABE SEIYAKU CO., LTD. (JP) | 1998-09-15 | — | — | US | disclosed |
| EP-0731091-A1 | 2-OXOINDOLINE DERIVATIVE | TANABE SEIYAKU CO., LTD. (JP) | 1996-09-11 | — | — | EP | disclosed |
| US-5434148-A | β-carboline derivative | TANABE SEIYAKU CO., LTD. (JP) | 1995-07-18 | — | — | US | disclosed |
| EP-0572235-A2 | Beta-carboline derivatives with anticholecystoquinine activity | TANABE SEIYAKU CO., LTD. (JP) | 1993-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759763-B2 | Syntheses of N-heterocyclic carbenes and intermediates therefor | GRHPR, DDC, NDC1 | MAPT 3063/4885GAA 3601/4885KDM4E 3800/4885 |
| US-20070265296-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | MAPT 869/4885GAA 4352/4885KDM4E 1462/4885 |
| US-11572348-B2 | Syntheses of N-heterocyclic carbenes and intermediates therefor | GRHPR, DDC, NDC1 | MAPT 3063/4885GAA 3601/4885KDM4E 3800/4885 |
| US-20090062341-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | MAPT 869/4885GAA 4352/4885KDM4E 1462/4885 |
| US-20210317088-A9 | SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR | GRHPR, DDC, NDC1 | MAPT 3063/4885GAA 3601/4885KDM4E 3800/4885 |
| US-20200354323-A1 | SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR | GRHPR, DDC, NDC1 | MAPT 3063/4885GAA 3601/4885KDM4E 3800/4885 |
| US-20090221820-A1 | Ligands for Transition-Metal-Catalyzed Cross-Couplings, and Methods of Use Thereof | SOD1, TIMCC, TST | MAPT 3058/4885GAA 1562/4885KDM4E 4308/4885 |
| US-11205755-B2 | Compound for organic electronic element, organic electronic element using same, and electronic device thereof | PIEZO1, OR51E2, ORAI2 | MAPT 1224/4885GAA 3607/4885KDM4E 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.